ARTICLE
Dear Editor,
We read with great interest the recent paper by Koga et al. [1]
showing the presence of IFN-alpha immunostained cells in the psoriatic
epidermis, which the authors take to be evidence for the presence of IFN-alpha
producing epidermal T-cells in psoriasis. This is indisputable. However,
it seems to us that the authors have overlooked another very interesting
finding ; that is the expression of IFN-alpha by keratinocytes in
the epidermis of psoriatic patients. In particular, in Fig. 2 and
Fig. 3 of their paper [1], it seems that there is a significant
amount of positive IFN-alpha immunostaining within the cytoplasm of keratinocytes.
This surely cannot be background or non-specific staining ? We note
that in another study [2] published in this journal, that micrographs
of lesional psoriatic skin showing strong epidermal IFN-alpha -immunostaining,
which was decreased by mometasone furoate treatment, were shown. Remarkably,
the authors of that study also failed to remark on what would also appear
to be expression of IFN-alpha by psoriatic keratinocytes.
We have noted that keratinocytes derived from non-lesional skin of psoriasis
patients [3] and grown in serum free keratinocyte growth medium can produce
significant amounts of secreted IFN-alpha which can be measured by ELISA
in the culture supernatants. Keratinocyte cultures (80 % confluent)
were harvested from 25 cm2 flasks containing 10 mls
of KSFM growth media [3]. Keratinocyte cultures from five different normal
donors prepared by the same method [3] did not secrete any detectable
IFN-alpha using an ELISA with a detection limit of 3 pg/ml. However,
two of four cultures from psoriatic patients produced readily detectable
IFN-alpha (mean = 32 ± 12 pg/ml). These cells
had been cultured for 3-5 passages and cultures did not contain any
T-cells.There is no record of human fibroblasts or melanocytes producing
IFN-alpha , so keratinocytes would seem the most likely source of the
cytokine.
The question remains what induces IFN-alpha production in keratinocytes ?
Ourselves and others have shown that keratinocytes can produce interleukin
(IL)-18 [4-7], and that in lesional psoriasitic skin there is strong
epidermal immunostaining for IL-18 [7, 8]. We found staining through
out the spinous and basal layers. There was a corresponding 2.7-fold increase
in IL-18 mRNA over levels in normal skin, as measured by RT-PCR,
in 14 patients [7]. IL-18 immunostaining is absent in normal
skin, but is also present in the basal layer of non-lesional psoriatic
skin. The basal layer of the epidermis is where the dividing cells which
establish in vitro keratinocyte cultures originate from.
IL-18 participates in a number of inflammatory conditions including
rheumatoid arthritis where it can contribute to disease pathology by inducing
pro-inflammatory mediators such as IFN-alpha and TNF-b (reviewed in
[9]). In addition, previously we have reported that psoriatic lesional
epidermis expresses 5.2-fold higher levels of mRNA, for the IL-18 receptor
measured by RT-PCR [7]. A possibility is that autocrine IL-18 release
stimulates IFN-alpha expression in psoriatic keratinocytes. The chemokines
IP-10, MCP-1 and RANTES ; the adhesion molecule ICAM-1 ; and
HLA-DR are induced in keratinocytes by IFN-alpha and are expressed at
high levels in psoriatic epidermis (reviewed in [10]). If keratinocyte
damage induces IL-18, followed by IFN-alpha , this would provide an autocrine
amplification loop for epidermal inflammation. What induces the IL-18 ?
Keratinocyte damage by microbes ? Or by other environmental agents ?
We know that some of these (streptococcal infection and physical trauma)
are involved in triggering psoriasis.
There are some previous reports of IFN-alpha expression by keratinocytes.
Basal keratinocytes in biopsies from lichen planus patients express IFN-alpha
mRNA [11] as do kerati nocytes in skin from contact sensitisation reactions
[12]. In the latter study, IFN-alpha protein was also detected by immunostaining
and was co-localised with cytokeratin expression. IL-18 expression
is induced in keratinocytes in vitro by contact sensitisers [13].
Moreover, the expression of IFN-alpha by keratinocytes may be important
in determining the development of the T-helper cell development down the
TH-1 pathway, which is seen in psoriasis. For many years a dogma
has persisted that IFN-alpha is an exclusively "T-cell cytokine".
We would like to propose that this is an outmoded concept and that under
conditions of extreme inflammation, that the keratinocyte-psoriatic or
otherwise- can also express IFN-alpha and direct the course of T-cell
activation in the skin.
We would like to thank The Psoriasis Association (UK) and the Foundation
for Skin Research (Edinburgh) for funding these studies and Felicity Boyd
for performing RT-PCR.
References
1
Koga T, Duan H, Urabe K, Furue M. In situ localization of IFN-gamma-positive
cells in psoriatic lesional epidermis Eur J Dermatol 2002; 12:
20-3.
2
Berti E, Cerri A, Marzano AV, Richelda R, Bianchi B, Caputo R. Mometasone
furoate decreases adhesion molecule expression in psoriasis. Eur J
Dermatol 1988; 8; 421-6.
3
Jackson M, Howie SEM, Weller R, Hunter JAA, McKenzie RC. Psoriatic
keratinocytes show reduced IRF-1 and STAT-1alpha activation in response
to gamma-IFN. FASEB J 1999; 13:495-502.
4
Companjen AR, van der Velden VHJ, Vooys A, Debets R, Benner R, Prens
EP. Human keratinocytes are major producers of IL-18: predominant expression
of the unprocessed form. Eur Cytokine Network 2000; 11: 383-90.
5
Mee JB, Alam Y, Groves RW. Human keratinocytes constitutively produce
but do not process interleukin-18. Br J Dermatol 2000; 143: 330-6.
6
Koizumi H, Sato-Matsumura KC, Nakamura H, Shida K, Kikkawa S, Matsumoto
M, Toyoshima K, Seya T. Distribution of IL-18 and IL-18 receptor in human
skin: various forms of IL-18 are produced in keratinocytes. Arch Dermatol
Res 2001; 293: 375-33.
7
McKenzie RC, Boyce F, Forsey R, Gracie A, Szepietowski JC, Weller
R, Sabin E, Howie SEM. Psoriatic skin expresses high levels of interleukin-18
(IL-18) and IL-18 receptor (IL-18R). Br J Dermatol 2000; 142: 618.
8
Ohta Y, Hamada Y, Katsuoka K. Expression of IL-18 in psoriasis. Arch
Dermatol Res 2001; 293: 334-42.
9
McInnes IB, Gracie JA, Leung BP, Liew FY. Interleukin 18: a participant
in chronic inflammation. Immunology Today. 2000; 21: 312-5.
10
Krueger JG. The immunologic basis for the treatment of psoriasis with
new biologic agents. J Acad Am J Dermatol 2002; 46: 1-23.
11
Fayyazi A, Schweyer S, Soruri A, Duong LQ, Radzun HJ, Peters J, Parwaresch
R, Berger HT. Lymphocytes and altered keratinocytes express interferon-gamma
and interleukin 6 in lichen planus. Arch Dermatol Res 1999; 291:
485-90.
12
Howie SEM, Aldridge RD, McVittie E, Forsey RJ, Sands C, Hunter JAA.
Epidermal keratinocyte production of interferon-gamma immunoreactive protein
and mRNA is an early event in allergic contact dermatitis. J Invest
Dermatol 1996. 106: 1218-223.
13
Naik SM, Cannon G, Burbach JG, Singh SR, Swerlich RA, Wilcox JN, Ansel
JG, Caughman SW. Human keratinocytes constitutively express interleukin-18
and secrete biologically active interleukin-18 after treatment with pro-inflammatory
mediators and dichlorobenzene. J Invest Dermatol 1999; 113: 766-72.
|